The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.
about
CRIF1 interacting with CDK2 regulates bone marrow microenvironment-induced G0/G1 arrest of leukemia cellsThree-Dimensional Microfluidic Tri-Culture Model of the Bone Marrow Microenvironment for Study of Acute Lymphoblastic LeukemiaCancer stem cells in basic science and in translational oncology: can we translate into clinical application?Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemiaAcquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.MIP-1α/CCL3-mediated maintenance of leukemia-initiating cells in the initiation process of chronic myeloid leukemia.Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.The impact of redox and thiol status on the bone marrow: Pharmacological intervention strategies.Oxidative stress and therapeutic opportunities: focus on the Ewing's sarcoma family of tumors.Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.Therapeutic implications of disorders of cell death signalling: membranes, micro-environment, and eicosanoid and docosanoid metabolismCuring chronic myeloid leukemia.Role of integrin alpha4 in drug resistance of leukemiaDPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia.Normal and leukemic stem cell niches: insights and therapeutic opportunities.BCR-ABL1-positive microvesicles malignantly transform human bone marrow mesenchymal stem cells in vitro.Reciprocal Interactions of Leukemic Cells with Bone Marrow Stromal Cells Promote Enrichment of Leukemic Stem Cell Compartments in Response to Curcumin and DaunorubicinChaetocin antileukemia activity against chronic myelogenous leukemia cells is potentiated by bone marrow stromal factors and overcomes innate imatinib resistance.The role and clinical implications of the endosteal niche and osteoblasts in regulating leukemia.High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia.Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors.Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway.Characterization of leukemic cell behaviors in a soft marrow mimetic alginate hydrogel.Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment.[Chronic myeloid leukemia stem cells: cross-talk with the niche].
P2860
Q24336990-822EC121-FF8A-4CA2-9694-1FAA6D80450FQ27313269-3B73E23B-B541-4B89-A91F-09E8161A534AQ28081844-2B52B88D-B0FF-4F43-9777-EE6052F4234EQ34173253-BDA74544-6407-4013-9EB2-31B813C665E3Q35409569-296D6555-2AAA-4686-9ADC-303E39782334Q35612803-4A595759-57D1-4478-883A-83FB3ACE58ADQ35679353-9A238667-E28A-4F0B-9CF0-ED6E01EDE395Q37322180-1F891727-D6A9-46EF-9757-55193B209753Q37723478-1EA1C174-A5FB-4468-8DE9-FBF73DA285B0Q37800633-BB9112E7-D239-4249-91B9-0C2871FFF4E0Q37845832-6F5B0432-90AD-4912-9FFE-B09E6FA93B71Q37865381-4AF60802-880C-4099-8CC3-B55B4C1863EDQ37988008-D54CA768-4F2B-4645-BAC8-67206526D20DQ37992839-49465A22-472C-4957-B88F-4D8028281AFAQ38218126-5DA85CD6-60DD-4063-B4A8-52CF2A5DF58BQ38265115-34554459-06FB-4209-B9CE-D6C705A9419CQ38369894-BD3ECDA0-5EFC-4036-8386-E38B0B8DE23FQ38694287-6AA35342-3BCE-44C5-B6B3-0B43CE6C3AF8Q38706127-21C6AFB5-18A4-41A2-AA7B-6AF9D44705AFQ38946587-E2A4D265-C5C1-442B-8A4B-E55BAA420922Q39172384-A0DD1E1A-B1BD-477A-B818-B34843B54E91Q39702824-E42A0398-A12F-486C-9727-E3E2FA7B93C1Q41575103-C0194FCB-78C3-4296-865F-3706E4FB93F6Q42366558-10D06944-7E44-472E-AB08-2437F2B525D9Q46212516-F7D25C51-6058-4AEB-9293-FA1EB4F42A2CQ47117016-8C8514DB-E4C7-4CE4-A8F5-E917E79C5BEDQ51566420-19F8A0CD-1C95-406A-B413-87D149792A82Q54354799-7C5FE9F9-86C7-4644-95CF-ACC2707B8EFA
P2860
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.
@ast
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.
@en
type
label
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.
@ast
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.
@en
prefLabel
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.
@ast
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.
@en
P2093
P2860
P1476
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.
@en
P2093
Joel Tolentino
Lori A Hazlehurst
Rajesh R Nair
P2860
P304
P356
10.1016/J.BCP.2010.04.003
P407
P577
2010-04-09T00:00:00Z